1
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al;
Asian Oncology Summit. Management of hepatocellular carcinoma in
Asia: Consensus statement from the Asian Oncology Summit 2009.
Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
No authors listed. A new prognostic system
for hepatocellular carcinoma: a retrospective study of 435
patients: the Cancer of the Liver Italian Program (CLIP)
investigators. Hepatology. 28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI
|
3
|
Huitzil-Melendez FD, Capanu M, O’Reilly
EM, Duffy A, Gansukh B, Saltz LL and Abou-Alfa GK: Advanced
hepatocellular carcinoma: Which staging systems best predict
prognosis? J Clin Oncol. 28:2889–2895. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Takanishi DM Jr, Severino R and Wong LL:
The Cancer of the Liver Italian Program (CLIP) score: Validation of
a new prognostic system for hepatocellular carcinoma. Hawaii Med J.
66:209–212. 2007.PubMed/NCBI
|
5
|
Levy I and Sherman M; Liver Cancer Study
Group of the University of Toronto. Staging of hepatocellular
carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging
systems in a cohort of 257 patients in Toronto. Gut. 50:881–885.
2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
7
|
Marrero JA, Fontana RJ, Barrat A, Askari
F, Conjeevaram HS, Su GL and Lok AS: Prognosis of hepatocellular
carcinoma: Comparison of 7 staging systems in an American cohort.
Hepatology. 41:707–716. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cillo U, Vitale A, Grigoletto F, Farinati
F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D’Amico F, et
al: Prospective validation of the Barcelona Clinic Liver Cancer
staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J; EASL Panel of Experts on HCC; European Association for
the Study of the Liver. Clinical management of hepatocellular
carcinoma. Conclusions of the Barcelona-2000 EASL conference. J
Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kudo M, Chung H and Osaki Y: Prognostic
staging system for hepatocellular carcinoma (CLIP score): Its value
and limitations, and a proposal for a new staging system, the Japan
Integrated Staging Score (JIS score). J Gastroenterol. 38:207–215.
2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
No authors listed. Liver Cancer Study
Group of Japan: The general rules for the clinical and pathological
study of primary liver cancer. Jpn J Surg. 19:98–129. 1989.
View Article : Google Scholar
|
12
|
Kudo M, Chung H, Haji S, Osaki Y, Oka H,
Seki T, Kasugai H, Sasaki Y and Matsunaga T: Validation of a new
prognostic staging system for hepatocellular carcinoma: The JIS
score compared with the CLIP score. Hepatology. 40:1396–1405. 2004.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Gomaa AI, Hashim MS and Waked I: Comparing
staging systems for predicting prognosis and survival in patients
with hepatocellular carcinoma in Egypt. PLoS One. 9:e909292014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW,
Lin HC, Lee RC, Chiou YY, Lee FY and Huo TI: Performance status in
patients with hepatocellular carcinoma: Determinants, prognostic
impact, and ability to improve the Barcelona Clinic Liver Cancer
system. Hepatology. 57:112–119. 2013. View Article : Google Scholar
|
16
|
Montano-Loza AJ: Clinical relevance of
sarcopenia in patients with cirrhosis. World J Gastroenterol.
20:8061–8071. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Osaki Y and Nishikawa H: Treatment for
hepatocellular carcinoma in Japan over the last three decades: Our
experience and published work review. Hepatol Res. 45:59–74. 2015.
View Article : Google Scholar :
|
18
|
Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY,
Park YO, Kim WT and Byun JH: Comparison of 7 staging systems for
patients with hepatocellular carcinoma undergoing transarterial
chemoembolization. Cancer. 112:352–361. 2008. View Article : Google Scholar
|
19
|
Kitai S, Kudo M, Minami Y, Ueshima K,
Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y,
et al: A new prognostic staging system for hepatocellular
carcinoma: Value of the biomarker combined Japan integrated staging
score. Intervirology. 51(Suppl 1): 86–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yamasaki T, Kurokawa F, Shirahashi H,
Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency
ablation therapy with combined angiography and computed tomography
assistance for patients with hepatocellular carcinoma. Cancer.
91:1342–1348. 2001. View Article : Google Scholar : PubMed/NCBI
|
21
|
Park JW, Amarapurkar D, Chao Y, Chen PJ,
Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, et al:
Consensus recommendations and review by an International Expert
Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver
Int. 33:327–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kudo M, Izumi N, Kokudo N, Matsui O,
Sakamoto M, Nakashima O, Kojiro M and Makuuchi M; HCC Expert Panel
of Japan Society of Hepatology. Management of hepatocellular
carcinoma in Japan: Consensus-Based Clinical Practice Guidelines
proposed by the Japan Society of Hepatology (JSH) 2010 updated
version. Dig Dis. 29:339–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hanley JA and McNeil BJ: The meaning and
use of the area under a receiver operating characteristic (ROC)
curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI
|
24
|
Pencina MJ and D’Agostino RB: Overall C as
a measure of discrimination in survival analysis: Model specific
population value and confidence interval estimation. Stat Med.
23:2109–2123. 2004. View
Article : Google Scholar : PubMed/NCBI
|
25
|
Zhao J, Yan T, Huang Z, Bi X, Zhao H, Zhou
J, Li Z, Li Y, Li C and Cai J: Evaluations of seven different
clinical staging systems for Chinese patients with hepatocellular
carcinoma undergoing curative resection. Zhonghua Yi Xue Za Zhi.
94:903–907. 2014.(In Chinese). PubMed/NCBI
|
26
|
Cillo U, Bassanello M, Vitale A,
Grigoletto FA, Burra P, Fagiuoli S, D’Amico F, Ciarleglio FA,
Boccagni P, Brolese A, et al: The critical issue of hepatocellular
carcinoma prognostic classification: Which is the best tool
available? J Hepatol. 40:124–131. 2004. View Article : Google Scholar
|
27
|
Collette S, Bonnetain F, Paoletti X,
Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Bedenne L
and Barbare JC: Prognosis of advanced hepatocellular carcinoma:
Comparison of three staging systems in two French clinical trials.
Ann Oncol. 19:1117–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Omata M, Lesmana LA, Tateishi R, Chen PJ,
Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, et al: Asian
Pacific Association for the Study of the Liver consensus
recommendations on hepatocellular carcinoma. Hepatol Int.
4:439–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Guglielmi A, Ruzzenente A, Pachera S,
Valdegamberi A, Sandri M, D’Onofrio M and Iacono C: Comparison of
seven staging systems in cirrhotic patients with hepatocellular
carcinoma in a cohort of patients who underwent radiofrequency
ablation with complete response. Am J Gastroenterol. 103:597–604.
2008. View Article : Google Scholar
|